79 related articles for article (PubMed ID: 9379441)
21. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies.
Wessale JL; Adler AL; Novosad EI; Calzadilla SV; Dayton BD; Marsh KC; Winn M; Jae HS; von Geldern TW; Opgenorth TJ; Wu-Wong JR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():112S-117S. PubMed ID: 12193067
[TBL] [Abstract][Full Text] [Related]
22. Functional role for glycosylated subtypes of rat endothelin receptors.
Shraga-Levine Z; Sokolovsky M
Biochem Biophys Res Commun; 1998 May; 246(2):495-500. PubMed ID: 9610390
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies.
Wu-Wong JR; Dixon DB; Chiou WJ; Sorensen BK; Liu G; Jae HS; Tasker A; von Geldern TW; Winn M; Opgenorth TJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():107S-111S. PubMed ID: 12193066
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and structure-activity relationships of a new model of arylpiperazines. 4. 1-[omega-(4-Arylpiperazin-1-yl)alkyl]-3-(diphenylmethylene) - 2, 5-pyrrolidinediones and -3-(9H-fluoren-9-ylidene)-2, 5-pyrrolidinediones: study of the steric requirements of the terminal amide fragment on 5-HT1A affinity/selectivity.
López-Rodríguez ML; Morcillo MJ; Rovat TK; Fernández E; Vicente B; Sanz AM; Hernández M; Orensanz L
J Med Chem; 1999 Jan; 42(1):36-49. PubMed ID: 9888831
[TBL] [Abstract][Full Text] [Related]
25. Muscarinic subtype affinity and functional activity profile of 1-methyl-2-(2-methyl-1,3-dioxolan-4-yl)pyrrolidine and 1-methyl-2-(2-methyl-1,3-oxathiolan-5-yl)pyrrolidine derivatives.
Dei S; Angeli P; Bellucci C; Buccioni M; Gualtieri F; Marucci G; Manetti D; Matucci R; Romanelli MN; Scapecchi S; Teodori E
Biochem Pharmacol; 2005 Jun; 69(11):1637-45. PubMed ID: 15896343
[TBL] [Abstract][Full Text] [Related]
26. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta.
Loomis ED; Sullivan JC; Osmond DA; Pollock DM; Pollock JS
J Pharmacol Exp Ther; 2005 Dec; 315(3):1058-64. PubMed ID: 16144972
[TBL] [Abstract][Full Text] [Related]
27. Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats.
Nishida M; Okada Y; Akiyoshi K; Eshiro K; Takoaka M; Gariepy CE; Yanagisawa M; Matsumura Y
Eur J Pharmacol; 2004 Aug; 496(1-3):159-65. PubMed ID: 15359489
[TBL] [Abstract][Full Text] [Related]
28. ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
Jarvis MF; Wessale JL; Zhu CZ; Lynch JJ; Dayton BD; Calzadilla SV; Padley RJ; Opgenorth TJ; Kowaluk EA
Eur J Pharmacol; 2000 Jan; 388(1):29-35. PubMed ID: 10657544
[TBL] [Abstract][Full Text] [Related]
29. Azole endothelin antagonists. 2. Structure-activity studies.
von Geldern TW; Kester JA; Bal R; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):968-81. PubMed ID: 8632420
[TBL] [Abstract][Full Text] [Related]
30. Potent and orally active ET(A) selective antagonists with 5,7-diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acid structures.
Yoshizumi T; Takahashi H; Ohtake N; Jona H; Sato Y; Kishino H; Sakamoto T; Ozaki S; Takahashi H; Shibata Y; Ishii Y; Saito M; Okada M; Hayama T; Nishikibe M
Bioorg Med Chem; 2004 May; 12(9):2139-50. PubMed ID: 15080914
[TBL] [Abstract][Full Text] [Related]
31. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease.
Saleh MA; Pollock JS; Pollock DM
J Pharmacol Exp Ther; 2011 Jul; 338(1):263-70. PubMed ID: 21471190
[TBL] [Abstract][Full Text] [Related]
32. Azole endothelin antagonists. 1. A receptor model explains an unusual structure-activity profile.
von Geldern TW; Hutchins C; Kester JA; Wu-Wong JR; Chiou W; Dixon DB; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):957-67. PubMed ID: 8632419
[TBL] [Abstract][Full Text] [Related]
33. Azole endothelin antagonists. 3. Using delta log P as a tool to improve absorption.
von Geldern TW; Hoffman DJ; Kester JA; Nellans HN; Dayton BD; Calzadilla SV; Marsh KC; Hernandez L; Chiou W; Dixon DB; Wu-Wong JR; Opgenorth TJ
J Med Chem; 1996 Feb; 39(4):982-91. PubMed ID: 8632421
[TBL] [Abstract][Full Text] [Related]
34. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists.
Riechers H; Albrecht HP; Amberg W; Baumann E; Bernard H; Böhm HJ; Klinge D; Kling A; Müller S; Raschack M; Unger L; Walker N; Wernet W
J Med Chem; 1996 May; 39(11):2123-8. PubMed ID: 8667356
[TBL] [Abstract][Full Text] [Related]
35. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.
Wu C; Chan MF; Stavros F; Raju B; Okun I; Mong S; Keller KM; Brock T; Kogan TP; Dixon RA
J Med Chem; 1997 May; 40(11):1690-7. PubMed ID: 9171878
[TBL] [Abstract][Full Text] [Related]
36. Effects of endothelin receptor antagonists on the plasma immunoreactive endothelin-1 level.
Opgenorth TJ; Wessale JL; Dixon DB; Adler AL; Calzadilla SV; Padley RJ; Wu-Wong JR
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S292-6. PubMed ID: 11078402
[TBL] [Abstract][Full Text] [Related]
37. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists.
Patt WC; Edmunds JJ; Repine JT; Berryman KA; Reisdorph BR; Lee C; Plummer MS; Shahripour A; Haleen SJ; Keiser JA; Flynn MA; Welch KM; Reynolds EE; Rubin R; Tobias B; Hallak H; Doherty AM
J Med Chem; 1997 Mar; 40(7):1063-74. PubMed ID: 9089328
[TBL] [Abstract][Full Text] [Related]
38. Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Jin C; Jeon Y; Kleven DT; Pollock JS; White JJ; Pollock DM
J Pharmacol Exp Ther; 2014 Nov; 351(2):467-73. PubMed ID: 25189702
[TBL] [Abstract][Full Text] [Related]
39. Toward the rational development of peptidomimetic analogs of the C-terminal endothelin hexapeptide: development of a theoretical model.
Macchia M; Barontini S; Ceccarelli F; Galoppini C; Giusti L; Hamdan M; Lucacchini A; Martinelli A; Menchini E; Mazzoni MR; Revoltella RP; Romagnoli F; Rovero P
Farmaco; 1998; 53(8-9):545-56. PubMed ID: 10081817
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET(A) receptor selectivity.
Boyd SA; Mantei RA; Tasker AS; Liu G; Sorensen BK; Henry KJ; von Geldern TW; Winn M; Wu-Wong JR; Chiou WJ; Dixon DB; Hutchins CW; Marsh KC; Nguyen B; Opgenorth TJ
Bioorg Med Chem; 1999 Jun; 7(6):991-1002. PubMed ID: 10428367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
